| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:IRAK4-IN-17 CAS:2183503-33-3 Package:1removed
|
Imidazo[1,2-b]pyridazine-3-carboxamide, N-[3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl]-6-[(3R)-3-piperidinylamino]- manufacturers
- IRAK4-IN-17
-
- $2500.00
-
2026-05-11
- CAS:2183503-33-3
- Purity:
- Supply Ability: 10g
|
| | Imidazo[1,2-b]pyridazine-3-carboxamide, N-[3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl]-6-[(3R)-3-piperidinylamino]- Basic information |
| | Imidazo[1,2-b]pyridazine-3-carboxamide, N-[3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl]-6-[(3R)-3-piperidinylamino]- Chemical Properties |
| density | 1.59±0.1 g/cm3(Predicted) | | pka | 8.57±0.46(Predicted) |
| | Imidazo[1,2-b]pyridazine-3-carboxamide, N-[3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl]-6-[(3R)-3-piperidinylamino]- Usage And Synthesis |
| Uses | IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM[1]. IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research[1]. | | IC 50 | IRAK4: 1.3 nM (IC50) | | References | [1] Yun Chen, et al. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. Eur J Med Chem. 2020 Mar 15;190:112092. DOI:10.1016/j.ejmech.2020.112092 |
| | Imidazo[1,2-b]pyridazine-3-carboxamide, N-[3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl]-6-[(3R)-3-piperidinylamino]- Preparation Products And Raw materials |
|